25
Aug
Iron Dextran Vs Iron Sucrose. This study aimed to evaluate the safety and efficacy of TDI CosmoFer in comparison to intravenous iron sucrose infusion Venofer in patients with chronic kidney disease CKD. 200mg iron given 3 times per week. Lowmolecularweight iron dextran CosmoFer is the only form of parenteral iron that can be administered as a total dose infusion TDI in the United Kingdom UK. The adverse reactions that have occurred.
For iron gluconate 20 95 CI 12 35. Confidence that iron sucrose or any other formulation of iron for intravenous administration is clearly safer than iron dextran. Iron sucrose and iron dextran dialysate concentration was below the lower limits of assay 2 ppm for system A. One formulation of parenteral iron is iron dextran which covers the old high molecular weight trade name DexFerrum and the much safer low molecular iron dextrans tradenames including Cosmofer and Infed. Iron sucrose has an occurrence of allergic reactions of less than 1 in 1000. Dialysate recovery of iron was negligible.
Dialyzer type or UFR did not affect iron removal.
If total dose of iron needed is high then iron dextran is preferred since the adverse events are not any higher than iron sucrose. THIS PROTOCOL REFERS TO LOW MOLECULAR WEIGHT IRON DEXTRAN COSMOFER 16 Response Due to iron metabolic pathways a rise in reticulocyte count will occur during the second week and thereafter provided. 0 54 mg system A and 547 2359 mg for system B. And for ferumoxytol 22 95 CI 11-43. 500 mg iron sucrose. Immediate ADRs were similar between the two study arms.